| Covariate | Person 1 |
|---|---|
| Sex | Male |
| Age | 63 |
| Race | Hispanic |
| SBP (mmHg) | 134.7 |
| Statin use | No |
| Anticoagulant use | No |
| BP medication use | Yes |
| Currently smoking | No |
| Oral diabetes medication use | Yes |
| Total cholesterol (mg/dL) | 181 (4.8 mmol/L) |
| HDL cholesterol (mg/dL) | 61 (1.4 mmol/L) |
| Hemoglobin A1c (%) | 6.1 (51.5 mmol/mol) |
| Serum creatinine (mg/DL) | 0.63 (53.0 μmol/L) |
| Urine albumin creatinine ratio (mg/g) | 301.6 |
| CVD history | No |
| CVD risk (10-yr risk, %) | |
| Myocardial infarction | 4 |
| Stroke | 1 |
| Microvascular risk (10-yr risk, %) | |
| Nephropathy | 5 |
| Retinopathy | 6 |
| Neuropathy | 6 |
| Drug ranking score (95% CI) based on network meta-analysis | |
| 1st | SGLT-2-i 1.0 [0.81,1.37] |
| 2nd | GLP-1RA 0.94 [0.593, 1.39] |
| 3rd | TZD 0.87 [0.65,1.27] |
| 4th | SU 0.86 [0.62, 1.31] |
| 5th | DPP-4 0.77 [0.55, 1.23] |
| 6th | Basal insulin 0.76 [0.27, 1.39] |